You are here

Electrophysiology & Arrhythmia


The FDA approved the Evera MRI Surescan implantable cardioverter defibrillator (ICD) as the first ICD system for use with MRI scans. The system is expected to be available this month.


Recent Headlines

FDA approves first MRI-compatible ICD system

The FDA approved the Evera MRI Surescan implantable cardioverter defibrillator (ICD) as the first ICD system for use with MRI scans. The system is expected to be available this month.

Trial: St. Jude's cardiac leadless pacemaker is safe and effective at 6 months

After six months of nonsurgical implantation with an active-fixation leadless cardiac pacemaker, 90 percent of patients had an acceptable pacing threshold and sensing amplitude, according to a prespecified analysis of an ongoing study. In addition, 6.7 percent of patients had device-related serious adverse events.

ACC plans to launch two atrial fibrillation registries

The American College of Cardiology (ACC) announced it plans on launching two clinical registry programs to track outcomes in patients with atrial fibrillation. The registries will be part of the National Cardiovascular Data Registry, which currently includes eight cardiovascular data registries.

FDA warns of deaths, adverse events with the Lariat device

The FDA issued a safety alert on July 13, warning of deaths and severe adverse events associated with the use of SentreHEART's Lariat suture delivery device for left atrial appendage (LAA) exclusion and preventing strokes in patients with atrial fibrillation.

Study finds 7% malfunction rate in CIEDs attributable to radiotherapy

A retrospective analysis found 7 percent of patients with cardiovascular implantable electronic devices (CIEDs) had a malfunction attributed to radiotherapy. All of the cases occurred during neuron-producing radiotherapy, prompting lead researcher Jonathan D. Grant, MD, to recommend the use of non-neutron-producing radiotherapy when clinically feasible.

Fewer than 10% of Medicare beneficiaries receive an ICD after MI

Fewer than 10 percent of older adults received an implantable cardioverter-defibrillator (ICD) following an MI, according to an analysis of Medicare beneficiaries who had low ejection fraction. Although the patients were at an increased risk of sudden cardiac death, only 8.1 percent were implanted with the device within a year of their MI event.

No anticoagulation bridging for elective procedures offers benefits

Here’s a bridge you may consider burning: anticoagulation bridging therapy for patients with atrial fibrillation who undergo an elective operation. A randomized clinical trial found no bridging after discontinuing warfarin led to no more thromboembolic events than bridging, with a lower risk of bleeding.

Sudden cardiac deaths are rare with pacemakers or ICDs

A prospective analysis found 4.3 percent of sudden cardiac deaths in San Francisco were in patients with pacemakers or implantable cardioverter-defibrillators (ICDs). Half of the deaths were related to the devices, and the most common cause of death was ventricular tachycardia or ventricular fibrillation.

Medtronic acquires CardioInsight and expands its AF business

Medtronic acquired CardioInsight Technologies in a debt-free deal announced on June 19 that increases Medtronic’s focus on atrial fibrillation and other arrhythmias. The deal was valued at approximately $93 million.

Life-threatening arrhythmias are rare when reducing cardiac telemetry

If hospitals and health systems reduce their use of cardiac telemetry in nonintensive care settings, they are unlikely to miss life-threatening arrhythmias, according to a single-center study. Life-threatening arrhythmias occurred in one of 2,645 patients.